The electrophilic 17-oxo-docosahexaenoic acid (17-oxo-DHA) enhances the anti-inflammatory potency of fluticasone propionate

Chiara Cipollina (Palermo, Italy), Chiara Cipollina, Serena Di Vincenzo, Caterina Di Sano, Mark Gjomarkaj, Elisabetta Pace

Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Session: Therapeutic approaches in inflammatory lung disease
Session type: Thematic Poster Session
Number: 3896
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Chiara Cipollina (Palermo, Italy), Chiara Cipollina, Serena Di Vincenzo, Caterina Di Sano, Mark Gjomarkaj, Elisabetta Pace. The electrophilic 17-oxo-docosahexaenoic acid (17-oxo-DHA) enhances the anti-inflammatory potency of fluticasone propionate. Eur Respir J 2015; 46: Suppl. 59, 3896

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The electrophilic 17-oxo-DHA enhances the anti-inflammatory efficacy of fluticasone propionate in COPD patients
Source: International Congress 2016 – Translational studies in lung disease
Year: 2016

Anti-inflammatory effects of formoterol and fluticasone propionate in bronchial epithelial cells
Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Year: 2015

Decoy chemokine neutraligands with anti-asthmatic activity
Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Year: 2015

A combination of thyme and ivy exerts potent anti-inflammatory and mucus-normalizing activity in vivo and inhibits 5-LO and PDE4
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014

LATE-BREAKING ABSTRACT: GW870086: A potent anti-inflammatory glucocorticoid with a novel pharmacological profile
Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment
Year: 2013


Anti-inflammatory effects of roflumilast N-oxide and dexamethasone in human bronchial epithelial cells stimulated with toll-like receptor agonists
Source: Annual Congress 2013 –The pulmonary epithelium: recent developments
Year: 2013


Enhanced anti-inflammatory gene expression in humans following inhaled budesonide
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013

Antiinflammatory properties of PAH drugs
Source: International Congress 2016 – New findings in mucosal immunology
Year: 2016

Demonstration of anti-inflammatory properties of an inhaled p38 inhibitor AZD7624
Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Year: 2015

A combination of thyme and primula dry extracts possesses antitussive activity and inhibits leukotriene formation
Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Year: 2013


Prolonged activity where it matters - the reversible esterfication of budesonide improves its topical anti-inflammatory efficacy and selectivity in the airways
Source: Eur Respir J 2001; 18: Suppl. 33, 21s
Year: 2001

Effect of the combination of doxofylline and montelukast on LPS-induced leukocyte migration to the lung
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014

Differential effects of simvastatin and dexamethasone on TLR3-induced anti-viral cytokines in asthmatic epithelium
Source: Annual Congress 2013 –Studies of asthma in man
Year: 2013

In vitro profile of the new inhaled pan-JAK inhibitor LAS194046
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014

Pharmacological characterization of CHI25243, a novel potent inhaled inhibitor of neutrophil elastase
Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models
Year: 2016



Synergistic effects of p38 MAPK inhibition with a corticosteroid in alveolar macrophages from corticosteroid insensitive asthma patients
Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Year: 2013

Simvastatin suppresses the activity of Th2 and Tc2 cells in atopic asthma and in COPD
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014

Anti-inflammatory effects of the novel PDE4 inhibitor CHF6001 on virus inducible cytokines
Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology
Year: 2014

Stimulation of IL-8 release in respiratory cell cultures by increasing IL1-beta concentrations: Effect of budesonide
Source: Annual Congress 2013 –Asthma: new mechanisms and markers
Year: 2013


Regulation of inflammatory cytokines in human immunocompetent cells by propranolol in vitro
Source: International Congress 2016 – Laboratory tests and cell biology in allergy and immunology
Year: 2016